Dr. YishanYe: Continued Validation of the Advantages of Haploidentical Transplantation — Moving Toward an Era of “Timely Access to Optimal Donors for All” | 2025 International Cell & Immunotherapy Congress 

Dr. YishanYe: Continued Validation of the Advantages of Haploidentical Transplantation — Moving Toward an Era of “Timely Access to Optimal Donors for All” | 2025 International Cell & Immunotherapy Congress 

To promote innovation in China’s cell therapy and immunotherapy fields, advance discussion of key scientific challenges, share the latest clinical research, and strengthen global collaboration and translational progress, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Immunology Society, and the Zhejiang Anti-Cancer Association—was held on November 13–16, 2025 in Hangzhou. 
Blood Science Update|China Expert Consensus on mNGS for Diagnosing Infections in Hematological Disorders (2024) 

Blood Science Update|China Expert Consensus on mNGS for Diagnosing Infections in Hematological Disorders (2024) 

The 2024 China Expert Consensus on metagenomic next-generation sequencing (mNGS) in hematological disorders, published in Blood Science, offers the first national guidance on how mNGS should be applied to infection diagnosis in this highly vulnerable population. Because hematological diseases and their treatments cause profound immunosuppression, infections remain a major cause of morbidity and mortality. Traditional microbiological tests (CMTs) frequently produce delayed or negative results, especially after antibiotic exposure. mNGS, which enables broad, unbiased pathogen detection, has therefore become an essential complementary tool. 
Blood Science Update|A Prognostic Analysis of Acute Leukemia Patients With Prior CNS Involvement Undergoing Umbilical Cord Blood Transplantation 

Blood Science Update|A Prognostic Analysis of Acute Leukemia Patients With Prior CNS Involvement Undergoing Umbilical Cord Blood Transplantation 

Published in Blood Science in 2025, the study led by Zichang Shen examines the impact of central nervous system leukemia (CNSL) on outcomes after umbilical cord blood transplantation (UCBT). CNSL remains a difficult manifestation of acute leukemia because leukemic cells within the CNS can evade systemic chemotherapy and drive relapse. Although allogeneic transplantation is the most effective curative approach for high-risk disease, the influence of prior CNS involvement on post-transplant outcomes has remained uncertain. Shen and colleagues therefore evaluated how a history of CNSL affects long-term prognosis following UCBT. 
Blood Science Update|Alpha-Enolase Drives AML Progression via MAPK/ERK Signaling: Condensed Summary 

Blood Science Update|Alpha-Enolase Drives AML Progression via MAPK/ERK Signaling: Condensed Summary 

The commentary “Alpha-enolase promotes progression of acute myeloid leukemia via MAPK/ERK signaling pathway” by Zhang et al., published in Blood Science (2025), examines the clinical and biological significance of ENO1 in acute myeloid leukemia (AML). ENO1, a glycolytic enzyme with additional regulatory roles, has been implicated in several solid tumors, but its function in AML had not been fully clarified. Through integrated analyses of patient samples, functional assays, transcriptomics, and in vivo models, the authors demonstrate that ENO1 is overexpressed in AML and promotes disease progression mainly through MAPK/ERK pathway activation.